IL302874A - Anti-Marco antibodies and their uses - Google Patents
Anti-Marco antibodies and their usesInfo
- Publication number
- IL302874A IL302874A IL302874A IL30287423A IL302874A IL 302874 A IL302874 A IL 302874A IL 302874 A IL302874 A IL 302874A IL 30287423 A IL30287423 A IL 30287423A IL 302874 A IL302874 A IL 302874A
- Authority
- IL
- Israel
- Prior art keywords
- cdr
- antibody
- seq
- sequence
- marco
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L5/00—Arrangements affording multiple use of the transmission path
- H04L5/003—Arrangements for allocating sub-channels of the transmission path
- H04L5/0044—Allocation of payload; Allocation of data channels, e.g. PDSCH or PUSCH
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W28/00—Network traffic management; Network resource management
- H04W28/02—Traffic management, e.g. flow control or congestion control
- H04W28/08—Load balancing or load distribution
- H04W28/082—Load balancing or load distribution among bearers or channels
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W74/00—Wireless channel access
- H04W74/08—Non-scheduled access, e.g. ALOHA
- H04W74/0833—Random access procedures, e.g. with 4-step access
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Signal Processing (AREA)
- Computer Networks & Wireless Communication (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063115272P | 2020-11-18 | 2020-11-18 | |
| US202163244662P | 2021-09-15 | 2021-09-15 | |
| PCT/US2021/059955 WO2022109178A1 (en) | 2020-11-18 | 2021-11-18 | Anti-marco antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL302874A true IL302874A (en) | 2023-07-01 |
Family
ID=81588283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL302874A IL302874A (en) | 2020-11-18 | 2021-11-18 | Anti-Marco antibodies and their uses |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11572407B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4247419A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023549555A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230121759A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021382658A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3198579A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL302874A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023005841A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202237648A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022109178A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202237648A (zh) | 2020-11-18 | 2022-10-01 | 美商開拓免疫醫療公司 | 抗marco抗體及其用途 |
| US20250011410A1 (en) * | 2021-11-23 | 2025-01-09 | Invetx, Inc. | Anti-ngf antibodies and uses thereof |
| US20260008844A1 (en) * | 2022-09-15 | 2026-01-08 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Use of anti-marco antibody with a checkpoint blockade antibody for the treatment of cancer |
| US20260126450A1 (en) * | 2022-10-12 | 2026-05-07 | Massachusetts Institute Of Technology | Library-scale methods for polypeptide functional analysis |
| WO2025102054A1 (en) * | 2023-11-09 | 2025-05-15 | Massachusetts Institute Of Technology | Methods of screening for secreted functional molecules |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5916766A (en) | 1996-05-23 | 1999-06-29 | Smithkline Beecham Corporation | Human marco scavenger receptor |
| US20060257359A1 (en) | 2005-02-28 | 2006-11-16 | Cedric Francois | Modifying macrophage phenotype for treatment of disease |
| US20100227415A1 (en) | 2007-07-24 | 2010-09-09 | Iss Immune System Stimulation Ab | Method and means for prediction of systemic lupus erythematosus susceptibility |
| US8597946B2 (en) | 2008-03-10 | 2013-12-03 | H. Lee Moffitt Caner Center and Research Institute, Inc. | Enhanced dendritic cells for cancer immunotherapy |
| KR20130108295A (ko) * | 2010-08-13 | 2013-10-02 | 베일러 리서치 인스티튜트 | 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제 |
| WO2012122396A1 (en) | 2011-03-08 | 2012-09-13 | Baylor Research Institute | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
| WO2016196612A1 (en) | 2015-06-01 | 2016-12-08 | The Rockefeller University | Anti-tumor agents and methods of use |
| WO2017062363A1 (en) | 2015-10-05 | 2017-04-13 | Joslin Diabetes Center | Methods of use of betatrophin |
| CA3049791A1 (en) | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| EP3612563A1 (en) | 2017-04-19 | 2020-02-26 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| TW201904588A (zh) | 2017-06-25 | 2019-02-01 | 美商西雅圖免疫公司 | 引導及導航控制蛋白質之製造及使用方法 |
| EP3668899A4 (en) | 2017-08-18 | 2020-09-02 | Celdara Medical, LLC | CELL-BASED THERAPIES TARGETING DISEASE-ASSOCIATED MOLECULAR MEDIATORS OF FIBROTIC, INFLAMMATORY AND AUTOIMMUNE DISEASES |
| PL3688155T3 (pl) | 2017-09-28 | 2023-09-11 | Immpact-Bio Ltd. | Uniwersalna platforma do wytwarzania hamującego chimerycznego receptora antygenowego (icar) |
| MX2020006654A (es) | 2017-12-22 | 2020-11-06 | Atossa Therapeutics Inc | Métodos intraductales de tratamiento de trastornos de mama. |
| MX387358B (es) | 2018-02-28 | 2025-03-18 | Pfizer | Variantes de il-15 y usos de las mismas |
| BR112021006100A2 (pt) | 2018-09-28 | 2021-07-20 | Immpact-Bio Ltd. | métodos para identificação de pares de receptor de antígeno ativador (acar)/receptor de antígeno quimérico inibitório (icar) para uso em terapias de câncer |
| JP2022514215A (ja) * | 2018-12-05 | 2022-02-10 | ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ | Rankアンタゴニストおよびその使用 |
| EP3906055A4 (en) | 2019-01-04 | 2023-01-04 | Trio Pharmaceuticals, Inc. | MULTISPECIFIC PROTEIN MOLECULES AND THEIR USES |
| WO2020162696A1 (ko) | 2019-02-08 | 2020-08-13 | 주식회사 굳티셀 | 암 치료를 위한 t 세포의 활성화 방법 |
| US20220152148A1 (en) | 2019-03-18 | 2022-05-19 | The Broad Institute, Inc. | Modulation of type 2 immunity by targeting clec-2 signaling |
| IL287801A (en) | 2019-05-07 | 2022-07-01 | Immunicom Inc | Increasing responses to checkpoint inhibitors by extracorporeal apheresis |
| GB2603044B (en) | 2019-06-11 | 2024-08-21 | Myeloid Therapeutics Inc | Macrophage specific engager compositions and methods of use thereof |
| KR20220054305A (ko) | 2019-07-31 | 2022-05-02 | 온코어 파마, 인크. | 면역 회피성 종양의 치료 |
| TW202237648A (zh) | 2020-11-18 | 2022-10-01 | 美商開拓免疫醫療公司 | 抗marco抗體及其用途 |
-
2021
- 2021-11-18 TW TW110143070A patent/TW202237648A/zh unknown
- 2021-11-18 EP EP21895613.4A patent/EP4247419A4/en active Pending
- 2021-11-18 IL IL302874A patent/IL302874A/en unknown
- 2021-11-18 CA CA3198579A patent/CA3198579A1/en active Pending
- 2021-11-18 JP JP2023529918A patent/JP2023549555A/ja active Pending
- 2021-11-18 AU AU2021382658A patent/AU2021382658A1/en active Pending
- 2021-11-18 KR KR1020237020512A patent/KR20230121759A/ko active Pending
- 2021-11-18 US US17/529,927 patent/US11572407B2/en active Active
- 2021-11-18 WO PCT/US2021/059955 patent/WO2022109178A1/en not_active Ceased
- 2021-11-18 MX MX2023005841A patent/MX2023005841A/es unknown
-
2022
- 2022-12-19 US US18/068,237 patent/US12378311B2/en active Active
-
2025
- 2025-07-03 US US19/260,221 patent/US20260172900A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3198579A1 (en) | 2022-05-27 |
| US20260172900A1 (en) | 2026-06-18 |
| JP2023549555A (ja) | 2023-11-27 |
| WO2022109178A9 (en) | 2023-07-13 |
| WO2022109178A1 (en) | 2022-05-27 |
| US11572407B2 (en) | 2023-02-07 |
| TW202237648A (zh) | 2022-10-01 |
| MX2023005841A (es) | 2023-08-16 |
| US12378311B2 (en) | 2025-08-05 |
| AU2021382658A1 (en) | 2023-07-06 |
| EP4247419A4 (en) | 2024-11-06 |
| US20220153832A1 (en) | 2022-05-19 |
| EP4247419A1 (en) | 2023-09-27 |
| US20240084000A1 (en) | 2024-03-14 |
| KR20230121759A (ko) | 2023-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12378311B2 (en) | Anti-MARCO antibodies and uses thereof | |
| JP7688579B2 (ja) | 抗trem2抗体の使用方法 | |
| JP7596263B2 (ja) | 4-1bb及び腫瘍関連抗原に結合する抗体構築物ならびにその使用 | |
| JP7759996B2 (ja) | 抗trem1抗体及び関連方法 | |
| US20240269176A1 (en) | Heterodimeric fc domain antibodies | |
| AU2020203065B2 (en) | Modified CK and CH1 domains | |
| EA052033B1 (ru) | Антитела к marco и их применение | |
| HK40096227A (zh) | 抗marco抗体和其用途 | |
| CN116635073A (zh) | 抗marco抗体和其用途 | |
| US20240376205A1 (en) | Targeted interferon alpha fusion proteins and methods of use | |
| JP2024544386A (ja) | Pd-l1抗原結合タンパク質及びその使用 | |
| HK40065337A (en) | Anti-trem1 antibodies and related methods | |
| EA049996B1 (ru) | Антитело к siglec-10 (варианты) |